MedTrace Logo

Semaglutide's Effect on Renal Hemodynamics and Function in Patients With Type 2 Diabetes Mellitus and Nephropathy

NCT06555146 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2024-08-15

No results posted yet for this study

Summary

The goal of this double-blinded, placebo-controlled, randomized, crossover study is to examine the effect of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), on renal hemodynamics and function in patients with type 2 diabetes mellitus (T2DM) and moderate chronic kidney disease (CKD).

The study will determine the effects of semaglutide on:

* Renal arterial blood flow, regional renal perfusion, and oxygenation
* Activity of the renin-angiotensin-aldosterone system (RAAS)
* The glomerular filtration rate (GFR)
* Sodium excretion in urine
* Blood pressure and heart rate

Conditions

  • Diabetes Mellitus, Type 2
  • Kidney Disease, Chronic

Interventions

DRUG

Semaglutide, 0.5 mg/mL

1 subcutaneous injection on baseline day

DRUG

Placebo, Saline

1 subcutaneous injection on baseline day

Sponsors & Collaborators

  • Bispebjerg Hospital

    lead OTHER

Principal Investigators

  • Ali Asmar, MD, PhD · Bispebjerg Hospital, Department of Clinical Physiology & Nuclear Medicine

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-31
Primary Completion
2025-03-31
Completion
2025-03-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06555146 on ClinicalTrials.gov